Other languages Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Market Closed - Swiss Exchange Other stock markets 11:30:44 2024-05-03 EDT			5-day change	1st Jan Change
9.31 ^CHF	-0.64%		-2.00%	-5.10%

04-25	Transcript : Santhera Pharmaceuticals Holding AG, 2023 Earnings Call, Apr 25, 2024
04-25	Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Santhera dans les chiffres noirs en 2023	04-25
Santhera Pharmaceuticals Swings to Profit in FY23; Revenue Grows	04-25
Santhera dank Catalyst-Deal mit gutem Finanzpuffer - ab 2026 Break-Even geplant	04-25
Santhera Pharmaceuticals Holding AG Reports Earnings Results for the Full Year Ended December 31, 2023	04-25
Spexis: sursis concordataire prolongé de 4 mois après réception d'un paiement	04-17
Santhera obtient un statut d'examen prioritaire en Chine pour le vamorolone	03-27
Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China	03-27
Santhera kommt mit möglicher Zulassung von Vamorolon in China entscheidend voran	03-27
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA	03-27
Santhera-Partner Catalyst Pharmaceuticals lanciert Agamree in den USA	03-14
Santhera: lancement de l'Agamree contre la myopathie de Duchenne aux USA	03-14
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical?s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology	02-21
Aktien Schweiz auf Erholungskurs	02-14
Santhera's New Study Shows Efficacy, Safety Data for Duchenne Muscular Dystrophy Treatment	02-14
Santhera veröffentlicht Daten über Vamorolon in Fachjournal 'Neurology'	02-14
Santhera lanciert DMD-Mittel Agamree zuerst in Deutschland - weltweite Premiere	01-15
Santhera lance Agamree contre la myopathie en commençant par l'Allemagne	01-15
Santhera Pharmaceuticals Holding AG Launches AGAMREE in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	01-15
Swiss Equities Get a Boost from UK’s Upside GDP Surprise	01-12
Santhera: feu vert pour le vamorolone contre la myopathie outre-Manche	01-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Santhera Pharmaceuticals Holding AG

Equities

SANN

CH1276028821

Other languages

Filters